<DOC>
	<DOC>NCT00708006</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.</brief_summary>
	<brief_title>A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed advanced solid malignancy Life expectancy of at least 3 months Age 18 years or older Acceptable liver function Acceptable renal function Acceptable hematologic status Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment. Received noninvestigational agent within 3 weeks before enrollment. Progressive CNS involvement including the need of corticosteroids Pregnant or breastfeeding women Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1 Known HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>